Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

Abroad (travel likely)Recruiting

Conditions

Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Evidera, a PPD Business Unit /ID# 238688, Morrisville, North Carolina, United States

  • PPD Development, LP /ID# 232134, Wilmington, North Carolina, United States

Study leads
  • ABBVIE INC.

    Study Director

    AbbVie